Globus Medical price target lowered to $80 from $95 at Stifel
Stifel analyst Thomas Stephan lowered the firm's price target on Globus Medical to $80 from $95 and keeps a Hold rating on the shares. 2026 revenue expectations are being lowered toward the low end of guidance due to weaker Nevro/ET performance and muted core Musculoskeletal growth, with slowing organic revenue growth potentially creating a challenging near-term setup despite more limited EPS downside risk, the analyst tells investors in a research note.
Stifel analyst Thomas Stephan lowered the firm's price target on Globus Medical to $80 from $95 and keeps a Hold rating on the shares.
2026 revenue expectations are being lowered toward the low end of guidance due to weaker Nevro/ET performance and muted core Musculoskeletal growth, with slowing organic revenue growth potentially creating a challenging near-term setup despite more limited EPS downside risk, the analyst tells investors in a research note.